Loading institutional data...
Loading institutional data...
Held by 289 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $72.74 today, the market must believe free cash flow compounds 15.2%/yr for a decade (off $57M normalized FCF).
The market's 15.2% is more conservative than its 3-yr track record.
2-stage DCF · 0.03B shares · net debt -$105M
mean 2908.8% · volatility σ 5101% · implied rate exceeded in 1/3 yrs
Central path = implied 15.2%/yr growth; shaded band = ±1σ (5101%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $175M buybacks = $175M returned on $78M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 19%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $105M covers all $25M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2020-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $912.0M 100.0% | $802.8M 100.0% | $624.8M 100.0% | $407.9M 100.0% | $233.4M 100.0% | $115.4M 100.0% | $82.0M 100.0% | $50.6M 100.0% | $28.6M 100.0% | $16.4M 100.0% |
| Cost of Revenue | $133.2M 14.6% | $123.0M 15.3% | $96.6M 15.5% | $66.1M 16.2% | $33.3M 14.3% | $17.6M 15.3% | $13.6M 16.6% | $10.1M 19.9% | $6.0M 21.1% | $3.9M 23.8% |
| Gross Profit | $778.8M 85.4% | $679.8M 84.7% | $528.2M 84.5% | $341.7M 83.8% | $200.1M 85.7% | $97.8M 84.7% | $68.4M 83.4% | $40.5M 80.1% | $22.5M 78.9% | $12.5M 76.2% |
| Research & Development | $103.2M 11.3% | $114.1M 14.2% | $116.5M 18.7% | $68.6M 16.8% | $37.4M 16.0% | $26.1M 22.6% | $12.8M 15.6% | $7.4M 14.6% | $6.2M 21.7% | $7.1M 43.2% |
| Selling, General & Admin | $624.6M 68.5% | $529.6M 66.0% | $452.0M 72.3% | $320.7M 78.6% | $202.6M 86.8% | $127.9M 110.8% | $90.5M 110.3% | $53.5M 105.8% | $32.4M 113.3% | $22.7M 138.1% |
| Total Operating Expenses | — | — | $568.5M 91.0% | $389.3M 95.5% | $240.0M 102.8% | $154.0M 133.4% | $103.3M 125.9% | $60.9M 120.4% | $38.6M 135.0% | $29.8M 181.3% |
| Operating Income | $51.0M 5.6% | $36.1M 4.5% | -$40.3M -6.4% | -$47.6M -11.7% | -$39.9M -17.1% | -$56.2M -48.7% | -$34.9M -42.5% | -$20.4M -40.3% | -$16.0M -56.0% | -$17.3M -105.0% |
| Interest Expense | $137K 0.0% | $22K 0.0% | $0 0.0% | $1.7M 0.4% | $2.1M 0.9% | $2.1M 1.8% | $2.1M 2.6% | $3.3M 6.5% | $1.8M 6.1% | $1.3M 7.9% |
| Interest & Investment Income | — | — | — | — | $125K 0.1% | $1.1M 0.9% | $3.8M 4.6% | $1.9M 3.7% | $203K 0.7% | $57K 0.3% |
| Other Income (Expense), net | $14.7M 1.6% | $22.4M 2.8% | $20.4M 3.3% | $3.3M 0.8% | -$2.1M -0.9% | -$880K -0.8% | $1.7M 2.1% | -$1.4M -2.9% | -$1.5M -5.3% | -$1.3M -7.8% |
| Pretax Income | $65.7M 7.2% | $58.5M 7.3% | -$19.9M -3.2% | -$44.3M -10.9% | -$42.0M -18.0% | -$57.1M -49.5% | -$33.2M -40.5% | -$21.8M -43.1% | -$17.5M -61.3% | -$18.5M -112.8% |
| Income Tax Expense | -$79.7M -8.7% | $4.9M 0.6% | $1.2M 0.2% | $613K 0.2% | $72K 0.0% | $115K 0.1% | $40K 0.0% | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | $145.4M 15.9% | $53.5M 6.7% | -$21.2M -3.4% | -$44.9M -11.0% | -$42.0M -18.0% | -$57.2M -49.6% | -$33.2M -40.5% | -$21.8M -43.1% | -$17.5M -61.3% | -$18.5M -112.8% |
| Per Share | ||||||||||
| EPS (Basic) | $4.95 | $1.80 | $-0.72 | $-1.60 | $-1.54 | $-2.19 | $-1.40 | — | — | — |
| EPS (Diluted) | $4.89 | $1.75 | $-0.72 | $-1.60 | $-1.54 | $-2.19 | $-1.40 | — | — | — |
| Weighted Avg Shares (Basic) | 29.4M | 29.8M | 29.3M | 28.1M | 27.3M | 26.1M | 23.8M | — | — | — |
| Weighted Avg Shares (Diluted) | 29.8M | 30.5M | 29.3M | 28.1M | 27.3M | 26.1M | 23.8M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 8-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 3.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 19.9 | 16.6 | 15.3 | 14.3 | 16.2 | 15.5 | 15.3 | 14.6 |
| Gross Profit | 80.1 | 83.4 | 84.7 | 85.7 | 83.8 | 84.5 | 84.7 | 85.4 |
| R&D | 14.6 | 15.6 | 22.6 | 16.0 | 16.8 | 18.7 | 14.2 | 11.3 |
| SG&A | 105.8 | 110.3 | 110.8 | 86.8 | 78.6 | 72.3 | 66.0 | 68.5 |
| Operating Income | -40.3 | -42.5 | -48.7 | -17.1 | -11.7 | -6.4 | 4.5 | 5.6 |
| Income Tax | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.2 | 0.6 | -8.7 |
| Net Income | -43.1 | -40.5 | -49.6 | -18.0 | -11.0 | -3.4 | 6.7 | 15.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on INSP: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| INSP | $2.1B | 14.9× | 30.4× | 2.3× | 13.6% | 85.4% | 15.9% | 18.6% | 18.6% | — | 289 |
Peers = companies sharing INSP's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.